Inspire Medical Systems (NYSE:INSP) Downgraded by Zacks Research to “Hold”

Inspire Medical Systems (NYSE:INSP) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday, Zacks reports.

Other equities research analysts also recently issued research reports about the stock. UBS Group began coverage on shares of Inspire Medical Systems in a research note on Tuesday, July 28th. They set a “sell” rating and a $39.00 target price for the company. Evercore set a $54.00 price target on Inspire Medical Systems in a research report on Tuesday, August 4th. Robert W. Baird upped their price objective on Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Freedom Capital raised Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings upgraded shares of Inspire Medical Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $66.50.

Inspire Medical Systems Trading Down 3.1%

Shares of INSP opened at $69.07 on Tuesday. The firm has a market cap of $2.00 billion, a PE ratio of 14.95, a price-to-earnings-growth ratio of 5.39 and a beta of 0.70. The company’s 50 day simple moving average is $60.79 and its 200-day simple moving average is $53.18. Inspire Medical Systems has a 12-month low of $38.91 and a 12-month high of $147.03.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.38. The firm had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. Inspire Medical Systems’s revenue for the quarter was down 7.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities research analysts forecast that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insider Activity

In other news, insider Jason Kelly sold 963 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider directly owned 18,985 shares of the company’s stock, valued at $1,130,556.75. This trade represents a 4.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Inspire Medical Systems in the second quarter valued at $211,341,000. ADAR1 Capital Management LLC grew its stake in shares of Inspire Medical Systems by 2,601.3% during the 1st quarter. ADAR1 Capital Management LLC now owns 405,197 shares of the company’s stock worth $20,900,000 after purchasing an additional 390,197 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Inspire Medical Systems by 66.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock worth $38,561,000 after purchasing an additional 344,221 shares during the period. Nantahala Capital Management LLC purchased a new position in shares of Inspire Medical Systems in the 2nd quarter valued at about $12,021,235. Finally, Bank of America Corp DE purchased a new position in shares of Inspire Medical Systems in the 2nd quarter valued at about $11,099,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for treating moderate to severe obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed for patients who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses a small implantable pulse generator, a breathing-sensing lead and a stimulation lead.